Abstract
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB.
MeSH Terms
Adolescent
Adult
Aged
Anti-Bacterial Agents/pharmacology
Antitubercular Agents/pharmacology
Child
Drug Resistance, Multiple, Bacterial
Female
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Mycobacterium tuberculosis/drug effects,isolation & purification
Sputum/microbiology
Tuberculosis, Multidrug-Resistant/epidemiology,microbiology
Turkmenistan/epidemiology
Uzbekistan/epidemiology
Chemicals
Anti-Bacterial Agents
Antitubercular Agents
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Cox Helen Suzanne
Médecins Sans Frontières Aral Sea Area Programme, Uzbekistan and Turkmenistan, Tashkent, Uzbekistan.
[email protected]
Orozco Juan Daniel
Male Roy
Ruesch-Gerdes Sabine
Falzon Dennis
Small Ian
Doshetov Darebay
Kebede Yared
Aziz Mohammed
References (10)
10 references, click to expand
-
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
JAMA. 2000 May 17;283(19):2537-45
PMID: 10815117
-
Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis.
Clin Infect Dis. 2001 Feb 1;32(3):373-80
PMID: 11170944
-
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
N Engl J Med. 2001 Apr 26;344(17):1294-303
PMID: 11320389
-
Acting on an environmental health disaster: the case of the Aral Sea.
Environ Health Perspect. 2001 Jun;109(6):547-9
PMID: 11445505
-
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB.
Int J Tuberc Lung Dis. 1999 May;3(5):451-3
PMID: 10331736
-
The nationwide tuberculosis drug resistance survey in Mongolia, 1999.
Int J Tuberc Lung Dis. 2002 Apr;6(4):289-94
PMID: 11936736
-
Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
Int J Tuberc Lung Dis. 2002 May;6(5):406-14
PMID: 12019916
-
Health sector reform in the former Soviet Republics of Central Asia.
Int J Health Plann Manage. 1998 Apr-Jun;13(2):131-47
PMID: 10185505
-
The dilemma of MDR-TB in the global era.
Int J Tuberc Lung Dis. 1998 Nov;2(11):869-76
PMID: 9848606
-
The burden of drug-resistant tuberculosis and mechanisms for its control.
Ann N Y Acad Sci. 2001 Dec;953:88-97
PMID: 11795426